Regencell Bioscience Holdings Ltd RGC Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$5.27 unchanged at close Nov 6
Last close · Previous close $5.27
- Market cap
- At the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$5.27unchangedFri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$5.27Nov 5
- Volume207.23KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume398.25KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $4.51 to $69.00; now $5.27
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RGC beat the S&P 500 in 3 of 6 periods.
| Period | RGC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RGC: down 28.3% S&P 500: down 5.6% | RGC trailed the S&P 500 by 22.7 percentage points Trailed |
| 3M | RGC: down 3.5% S&P 500: down 4.1% | RGC beat the S&P 500 by 0.6 percentage points Beat |
| YTD | RGC: down 74.9% S&P 500: up 8.7% | RGC trailed the S&P 500 by 83.6 percentage points Trailed |
| 1Y | RGC: down 60.3% S&P 500: up 10.9% | RGC trailed the S&P 500 by 71.2 percentage points Trailed |
| Long term | ||
| 3Y | RGC: up 1,281.1% S&P 500: up 75.0% +139.9% vs +20.5% a year | RGC beat the S&P 500 by 1,206.1 percentage points Beat |
| 5Y | RGC: up 887.0% S&P 500: up 67.8% +58.1% vs +10.9% a year | RGC beat the S&P 500 by 819.2 percentage points Beat |
$10,000 invested in RGC 5 years ago (Nov 5, 2021) would be worth about $98,699 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
RGC beat the S&P 500 in 3 of 6 periods.
| Period | RGC and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RGC: down 28.3% S&P 500: down 5.6% | RGC trailed the S&P 500 by 22.7 percentage points Trailed |
| 3M | RGC: down 3.5% S&P 500: down 4.3% | RGC beat the S&P 500 by 0.8 percentage points Beat |
| YTD | RGC: down 74.9% S&P 500: up 7.8% | RGC trailed the S&P 500 by 82.7 percentage points Trailed |
| 1Y | RGC: down 60.3% S&P 500: up 9.7% | RGC trailed the S&P 500 by 70.0 percentage points Trailed |
| Long term | ||
| 3Y | RGC: up 1,281.1% S&P 500: up 68.8% +139.9% vs +19.1% a year | RGC beat the S&P 500 by 1,212.3 percentage points Beat |
| 5Y | RGC: up 887.0% S&P 500: up 56.9% +58.1% vs +9.4% a year | RGC beat the S&P 500 by 830.1 percentage points Beat |
$10,000 invested in RGC 5 years ago (Nov 5, 2021) would be worth about $98,699 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$78.00
Closing high on . Now 93.2% below that record.
Split-adjusted daily closes since Jul 16, 2021.
Stock splits
1
38-for-1 on . One share bought before the first split is 38 shares today.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q4 FY26, the quarter ended Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY21 (Dec 31, 2020) | Not reported | Not reported | Not reported |
| Q4 FY21 (Jun 30, 2021) | Not reported | Not reported | Not reported |
| Q4 FY22 (Jun 30, 2022) | Not reported | Not reported | Not reported |
| Q4 FY23 (Jun 30, 2023) | Not reported | Not reported | Not reported |
| Q4 FY24 (Jun 30, 2024) | Not reported | Not reported | Not reported |
| Q4 FY25 (Jun 30, 2025) | Not reported | Not reported | Not reported |
| Q2 FY26 (Dec 31, 2025) | Not reported | Not reported | Not reported |
| Q4 FY26 (Jun 30, 2026) | Not reported | Not reported | Not reported |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Jun 30, 2022) | $0.00 | −$7.45M | Paused See the note under the price. |
| FY23 (Jun 30, 2023) | $0.00 | −$5.87M | Paused See the note under the price. |
| FY24 (Jun 30, 2024) | $0.00 | −$4.30M | Paused See the note under the price. |
| FY25 (Jun 30, 2025) | $0.00 | −$3.58M | −$0.01 |
| FY26 (Jun 30, 2026) | $0.00 | −$11.70M | −$0.02 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $14.27MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$295.81KAs of Jun 30, 2026
- Net cash$13.97MAs of Jun 30, 2026
- 10.77As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.02As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Regencell Bioscience Holdings Ltd
For more than 30 years, the TCM Practitioner whom Regencell partners with has treated patients with neurological disorders and infectious diseases. The TCM Practitioner’s TCM formulae candidates are derived from a TCM base formula and an adjustable formula which is developed based on his TCM brain theory, known as the “Sik-Kee Au TCM Brain Theory®”. Both Regencell and the TCM Practitioner are committed in giving back to the society and demonstrates its CARE through C aring for patients, A ccountability by maintaining a high standard of quality and integrity, R espect by valuing partnerships, teamwork and harmony and the E nthusiasm to improve the life of the underprivileged. Since its listing, Regencell through a joint venture with Honor Epic Enterprises Limited, formed Regencell Bioscience Asia Limited to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand, as Regencell aspires to be the global market leader for the provision of natural and holistic treatment for neurological disorders and infectious diseases.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hong Kong
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RGC news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RGC stock FAQ
What is RGC stock’s price today?
Regencell Bioscience Holdings (RGC) traded at $5.27 at the close on , unchanged from the previous close of $5.27. Over the past 52 weeks it has traded between $4.51 and $69.00.
If you invested $1,000 in RGC 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RGC on would be worth about $9,870 at the close on , a total return of +887.0%. The same $1,000 would be worth $397 if invested one year ago. Past performance doesn’t predict future returns.
Does RGC pay a dividend?
Regencell Bioscience Holdings hasn’t paid a dividend in the last twelve months.
What is RGC’s 52-week high and low?
Over the past 52 weeks RGC has traded as low as $4.51 and as high as $69.00. At $5.27 at the close on , it is 92.4% below that high and 16.9% above the low.
What is RGC’s all-time high?
RGC’s highest closing price was $78.00 on , adjusted for stock splits. At $5.27 at the close on , it is 93.2% below that record.
Has RGC stock ever split?
Yes, once: 38-for-1 on . One share bought before the first split would be 38 shares today.
How has RGC stock performed?
Including dividends and measured to the close on , RGC has returned −74.9% so far this year and −60.3% over the past year, and +887.0% over five years (+58.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Regencell Bioscience Holdings in?
Regencell Bioscience Holdings is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Hong Kong.
What exchange does RGC trade on?
Regencell Bioscience Holdings trades on the Nasdaq under the ticker symbol RGC. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.